e-52862 and Nociceptive-Pain

e-52862 has been researched along with Nociceptive-Pain* in 3 studies

Other Studies

3 other study(ies) available for e-52862 and Nociceptive-Pain

ArticleYear
Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
    Journal of medicinal chemistry, 2015, Mar-12, Volume: 58, Issue:5

    The synthesis and pharmacological activity of a new series of 4-aminotriazoles as potent σ1 receptor (σ1R) ligands are reported. The compounds were prepared using a 4-5-step process, involving as a key step a click chemistry reaction between ynamides and azides. The most active compounds exhibited nanomolar potency for the σ1R, and the selectivity over the σ2R was improved on decreasing the central amine basicity. It was concluded that in order to achieve good σ1R potency a minimum lipophilicity was required, while limiting to a defined range of cLogP avoided human ether-a-go-go-related gene channel inhibition. This made the most interesting derivatives to be concentrated in a narrow margin of lipophilicity. Among them, compound 13g exhibited the most potent in vivo antinociceptive properties, which are indicative of its antagonist character.

    Topics: Analgesics; Animals; Brain; Cell Membrane; Drug Evaluation, Preclinical; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Male; Mice; Molecular Structure; Morpholines; Nociceptive Pain; Radioligand Assay; Receptors, sigma; Sigma-1 Receptor; Structure-Activity Relationship; Triazoles

2015
Synthesis and biological evaluation of a novel sigma-1 receptor antagonist based on 3,4-dihydro-2(1H)-quinolinone scaffold as a potential analgesic.
    European journal of medicinal chemistry, 2014, May-22, Volume: 79

    The synthesis and sigma-1 receptor (σ1R) antagonist activity of a new series of 3,4-dihydro-2(1H)-quinolinone derivatives are reported. The new compounds were evaluated in vitro in sigma-1 and sigma-2 receptor-binding assays in guinea pig brain membranes. The structure-activity relationship led us to the promising derivative 7-(3-(piperidin-1-yl)propoxy)-1-(4-fluorobenzyl)-3,4-dihydro-2(1H)-quinolinone (35). The compounds with highest affinity and greatest selectivity were further profiled, and compound 35 had a high binding constant for sigma-1 receptor (Kiσ1 = 1.22 nM) and high sigma-1/2 selectivity (1066-fold). Thus, compound 35, which proved to be an antagonist of sigma-1 receptor, emerged as the most interesting candidate. In addition, compound 35 exerted dose-dependent anti-nociceptive effects in the formalin test. These characteristics suggested that the potent and selective compound 35 could be a potent candidate for pain treatment.

    Topics: Analgesics; Animals; Brain; Dose-Response Relationship, Drug; Formaldehyde; Guinea Pigs; Hydroquinones; Mice; Mice, Inbred Strains; Molecular Structure; Nociceptive Pain; Pain Measurement; Receptors, sigma; Sigma-1 Receptor; Structure-Activity Relationship

2014
Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain.
    Journal of medicinal chemistry, 2014, Dec-26, Volume: 57, Issue:24

    The discovery and synthesis of a new series of pyrimidines as potent sigma-1 receptor (σ1R) antagonists, associated with pharmacological antineuropathic pain activity, are the focus of this article. The new compounds were evaluated in vitro in σ-1 and σ-2 receptor binding assays. The nature of the pyrimidine scaffold was crucial for activity, and a basic amine was shown to be necessary according to the known pharmacophoric model. The most promising derivative was 5-chloro-2-(4-chlorophenyl)-4-methyl-6-(3-(piperidin-1-yl)propoxy)pyrimidine (137), which exhibited a high binding affinity to σ1R receptor (Ki σ1 = 1.06 nM) and good σ-1/2 selectivity (1344-fold). In in vivo tests, compound 137 exerted dose-dependent antinociceptive effects in mice formalin model and rats CCI models of neuropathic pain. In addition, no motor impairments were found in rotarod tests; acceptable pharmacokinetic properties were also noted. These data suggest compound 137 may constitute a novel class of drugs for the treatment of neuropathic pain.

    Topics: Animals; Behavior, Animal; Carbon Tetrachloride; Ether-A-Go-Go Potassium Channels; Guinea Pigs; Mice; Molecular Structure; Motor Activity; Neuralgia; Neuroprotective Agents; Nociceptive Pain; Piperidines; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, sigma; Sigma-1 Receptor; Structure-Activity Relationship

2014